• Issue

    Liver International: Volume 43, Issue 3

    i, 523-743
    March 2023
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE COVER

Free Access

Issue Cover

Koos de Wit,  Ulrich Beuers,  Anna Mukha,  Edwin C. A. Stigter,  M. Can Gulersonmez,  Jose M. Ramos Pittol,  Sabine Middendorp,  R. Bart Takkenberg,  Saskia W. C. van Mil, 
  • Page: i
  • First Published: 17 February 2023
Issue Cover

The cover image is based on the Original Article Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids by Koos de Wit et al., https://doi.org/10.1111/liv.15491.

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 523-527
  • First Published: 17 February 2023

EDITORIALS

Free Access

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Giuseppe Cabibbo,  Julien Edeline, 
  • Pages: 528-530
  • First Published: 17 February 2023
Free Access

HBV cure—The light at the end of the tunnel?

Lisa Sandmann,  Benjamin Maasoumy, 
  • Pages: 531-533
  • First Published: 17 February 2023

REVIEWS & META-ANALYSES

Open Access

Circadian rhythms and the liver

Rodolfo Costa,  Chiara Mangini,  Esther D. Domenie,  Lisa Zarantonello,  Sara Montagnese, 
  • Pages: 534-545
  • First Published: 28 December 2022
Free Access

Immunotherapy in hepatocellular carcinoma: How does underlying liver disease influence therapeutic strategy and outcomes?

Gael S. Roth,  François Villeret,  Thomas Decaens,  Philippe Merle,  Pierre Nahon, 
  • Pages: 546-557
  • First Published: 26 December 2022

LIVER DISEASE AND PUBLIC HEALTH

Open Access

Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017

Irina Tskhomelidze,  Shaun Shadaker,  Tinatin Kuchuloria,  Lia Gvinjilia,  Maia Butsashvili,  Muazzam Nasrullah,  Tamar Gabunia,  Amiran Gamkrelidze,  Vladimer Getia,  Lali Sharvadze,  Tengiz Tsertsvadze,  Jaba Zarqua,  Shota Tsanava,  Senad Handanagic,  Paige A. Armstrong,  Francisco Averhoff,  Peter Vickerman,  Josephine G. Walker, 
  • Pages: 558-568
  • First Published: 21 September 2022
Open Access

Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study

Jack Stone,  Aaron G. Lim,  Gregory J. Dore,  Annick Borquez,  Louise Geddes,  Richard Gray,  Jason Grebely,  Bezhad Hajarizadeh,  Jenny Iversen,  Lisa Maher,  Heather Valerio,  Natasha K. Martin,  Matthew Hickman,  Andrew R. Lloyd,  Peter Vickerman, 
  • Pages: 569-579
  • First Published: 28 October 2022

VIRAL HEPATITIS

COVID-19 and non-alcoholic fatty liver disease: Biological insights from multi-omics data

Carlos J. Pirola,  Silvia Sookoian, 
  • Pages: 580-587
  • First Published: 02 January 2023

Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies—A population-based study

Jacky C. L. Ho,  Joyce W. Y. Mak,  Terry C. F. Yip,  Hong Man Lam,  Tsz Yan Cheng,  Tsz On Lam,  Lai Shan Tam,  Man Fai Law,  Carmen K. M. Cheung,  Siew C. Ng,  Vincent W. S. Wong,  Grace L. H. Wong, 
  • Pages: 588-598
  • First Published: 14 December 2022

METABOLIC & TOXIC LIVER DISEASES

Performance of the Pooled Cohort Equations in non-alcoholic fatty liver disease: The Multi-Ethnic Study of Atherosclerosis

Jacqueline B. Henson,  Matthew J. Budoff,  Andrew J. Muir, 
  • Pages: 599-607
  • First Published: 19 November 2022

Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease

Ho Soo Chun,  Minjong Lee,  Jae Seung Lee,  Hye Won Lee,  Beom Kyung Kim,  Jun Yong Park,  Do Young Kim,  Sang Hoon Ahn,  Yong-Ho Lee,  Ji-Hye Kim,  Seung Up Kim, 
  • Pages: 608-625
  • First Published: 30 December 2022

Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression

Hongyu Xiang,  Chang Liu,  Zhuanglong Xiao,  Li Du,  Ning Wei,  Fang Liu,  Yuhu Song, 
  • Pages: 626-638
  • First Published: 10 November 2022

GUT-LIVER AXIS, IMMUNOLOGY, IMMUNE MEDIATED AND CHOLESTATIC DISEASES

Open Access

Disease burden in primary sclerosing cholangitis in the Netherlands: A long-term follow-up study

Kim N. van Munster,  Bregje Mol,  Jorn C. Goet,  Sanne N. van Munster,  Rinse K. Weersma,  Annemarie C. de Vries,  Adriaan J. van der Meer,  Akin Inderson,  Joost P. Drenth,  Karel J. van Erpecum,  Kirsten Boonstra,  Ulrich Beuers,  Marcel G. W. Dijkgraaf,  Cyriel Y. Ponsioen,  the EpiPSC2 Study Group , 
  • Pages: 639-648
  • First Published: 03 November 2022
Open Access

Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids

Koos de Wit,  Ulrich Beuers,  Anna Mukha,  Edwin C. A. Stigter,  M. Can Gulersonmez,  Jose M. Ramos Pittol,  Sabine Middendorp,  R. Bart Takkenberg,  Saskia W. C. van Mil, 
  • Pages: 649-659
  • First Published: 04 December 2022

CIRRHOSIS, LIVER FAILURE AND TRANSPLANTATION

Open Access

Relative adrenal insufficiency in the non-critically ill patient with cirrhosis: A systematic review and meta-analysis

Brian J. Wentworth,  Matthew Schliep,  Wendy Novicoff,  Helmy M. Siragy,  Calvin X. Geng,  Zachary H. Henry, 
  • Pages: 660-672
  • First Published: 10 November 2022
Open Access

Hyperammonaemia disrupts daily rhythms reversibly by elevating glutamate in the central circadian pacemaker

Daniel Granados-Fuentes,  Kevin Cho,  Gary J. Patti,  Rodolfo Costa,  Erik D. Herzog,  Sara Montagnese, 
  • Pages: 673-683
  • First Published: 11 November 2022

Association of sex-specific donor skeletal muscle index with surgical outcomes in living donor liver transplantation recipients

Ji-Hoon Sim,  Kyung-Won Kim,  YouSun Ko,  Hye-Mee Kwon,  Young-Jin Moon,  In-Gu Jun,  Sung-Hoon Kim,  Seonok Kim,  Jun-Gol Song,  Gyu-Sam Hwang, 
  • Pages: 684-694
  • First Published: 15 November 2022

LIVER CANCER

Open Access

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

Thomas Talbot,  Antonio D'Alessio,  Matthias Pinter,  Lorenz Balcar,  Bernhard Scheiner,  Thomas U. Marron,  Tomi Jun,  Sirish Dharmapuri,  Celina Ang,  Anwaar Saeed,  Hannah Hildebrand,  Mahvish Muzaffar,  Claudia A. M. Fulgenzi,  Suneetha Amara,  Abdul Rafeh Naqash,  Anuhya Gampa,  Anjana Pillai,  Yinghong Wang,  Uqba Khan,  Pei-Chang Lee,  Yi-Hsiang Huang,  Bertram Bengsch,  Dominik Bettinger,  Yehia I. Mohamed,  Ahmed Kaseb,  Tiziana Pressiani,  Nicola Personeni,  Lorenza Rimassa,  Naoshi Nishida,  Masatoshi Kudo,  Arndt Weinmann,  Peter R. Galle,  Ambreen Muhammed,  Alessio Cortellini,  Arndt Vogel,  David J. Pinato, 
  • Pages: 695-707
  • First Published: 28 December 2022

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab

Claudia Campani,  Jessica Bamba-Funck,  Bertille Campion,  Sabrina Sidali,  Lorraine Blaise,  Nathalie Ganne-Carrié,  Alix Demory,  Olivier Sutter,  Edouard Larrey,  Manon Evain,  Haroun Ghannouchi,  Mathilde Wagner,  Fabio Marra,  Angela Sutton,  Manon Allaire,  Jean-Charles Nault, 
  • Pages: 708-717
  • First Published: 29 November 2022

BASIC HEPATOLOGY

An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling

Taixiong Xue,  Lin Yue,  Guonian Zhu,  Zui Tan,  Hongyao Liu,  Cailing Gan,  Chen Fan,  Xingping Su,  Yuting Xie,  Tinghong Ye, 
  • Pages: 718-732
  • First Published: 30 November 2022
An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling

LIVER INTERNATIONAL IMAGES

The utility of F-18 FDG PET/CT for diagnosis and response evaluation of hepatosplenic tuberculosis

Dae-Weung Kim,  Soon-Ah Park,  Myoung Hyoun Kim, 
  • Pages: 733-734
  • First Published: 31 January 2023

LETTERS TO THE EDITOR

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease

Jinming Zhang,  Dabao Shang,  Qing Xie,  Xiaogang Xiang, 
  • Pages: 735-736
  • First Published: 28 December 2022

Opportunistic HCV screening in the general population: New insights for a graduated birth cohort approach

Federico Conti,  Martina Beltrami,  Gabriele Pagani,  Andrea Giacomelli, 
  • Pages: 737-738
  • First Published: 23 January 2023

Air pollutant exposure and non-alcoholic fatty liver disease: Sex considerations

Yuanbin Liu,  Mingkai Chen, 
  • Page: 739
  • First Published: 17 January 2023

Plasma corticosteroid-binding globulin concentrations are preserved in mild cirrhosis

Jessica H. Lee,  Marni A. Nenke,  Katerina Flabouris,  David J. Torpy,  Emily J. Meyer, 
  • Pages: 740-741
  • First Published: 23 January 2023

Author's reply: Plasma corticosteroid-binding globulin levels in cirrhosis

Brian J. Wentworth,  Matthew Schliep,  Helmy M. Siragy,  Zachary H. Henry, 
  • Pages: 742-743
  • First Published: 19 January 2023